LANCE Ultra Total BTK kits are designed for the detection of total BTK (phosphorylated and non-phosphorylated) in cell lysates using a simple, homogeneous LANCE Ultra assay (no wash steps). This assay can be used as a normalization assay for phospho-BTK detection, and is compatible with both adherent and suspension cells.
For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Please note control lysates are sold separately, catalog number TRF4021S.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are homogeneous (no wash) TR-FRET (time-resolved fluorescence resonance energy transfer) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second antibody is labeled with an acceptor fluorophore [ULight™ dye]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. Data are represented as ratiometric (665/615 nm X 10,000).
BTK is a cytoplasmic tyrosine kinase present in B-cells. It is associated with the B-cell receptor and receptors of the toll family. Upon activation, BTK will activate the Nf-kB pathway. This will induce maturation of B-cells into antibody producing cells and also increase the secretion of activating cytokines (such as IL-2). The protein is absent or non-functional in diseases such as aglobularia, but is also involved by hyperactivation in inflammation and auto-immune diseases. Also, several leukemia-like cancers have dysregulation of BTK.
|Assay Target Class||Protein|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Autoimmunity, Neuroscience, Oncology, Immuno-oncology|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.